Hua Naranmandura
YOU?
Author Swipe
View article: Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions
Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions Open
Hepatocellular carcinoma (HCC) ranks as the second most lethal malignancy worldwide, presenting formidable therapeutic challenges including tumor heterogeneity, complex microenvironment, and inefficient drug delivery. Conventional therapie…
View article: Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights
Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights Open
View article: Arsenic trioxide could promote SARS-CoV-2 NSP12 protein degradation
Arsenic trioxide could promote SARS-CoV-2 NSP12 protein degradation Open
The global dissemination and infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become a worldwide crisis with staggering confirmed cases and death tolls. Although prophylactic vaccines are widely applied to cur…
View article: Mutation in the Unrearranged <i>PML</i> Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia
Mutation in the Unrearranged <i>PML</i> Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia Open
Arsenic trioxide (ATO) is able to selectively target and degrade the disease-causing PML::RARα (P/R) oncoprotein in acute promyelocytic leukemia (APL) for curing the disease. However, some relapsed patients develop resistance to ATO due to…
View article: Trivalent Inorganic Arsenic and its Metabolites Drive Lung Cancer Progression by Inducing Immunosuppressive Alveolar Macrophages Via Activation of P62-Nrf2-Ho-1 Axis and Autophagolysosomal Dysfunction
Trivalent Inorganic Arsenic and its Metabolites Drive Lung Cancer Progression by Inducing Immunosuppressive Alveolar Macrophages Via Activation of P62-Nrf2-Ho-1 Axis and Autophagolysosomal Dysfunction Open
View article: Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives
Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives Open
Cyclin-dependent kinases (CDKs) are generally involved in the progression of cell cycle and cell division in normal cells, while abnormal activations of CDKs are deemed to be a driving force for accelerating cell proliferation and tumorige…
View article: Supplementary Table S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying all the reagents used in this study with information regarding the supplier, catalog number and RRID (antibodies).
View article: Supplementary Figure S5 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S5 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S5 displays how B2 trimer is essential for PML-RARA microspeckle formation in progenitors and PML NB disruption as well as PML/RARA degradation ex vivo, as well as for PML NB formation and sumoylation in vivo
View article: Supplementary Table S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying the information regarding the data collection and refinement statistics for the crystal structures of MBP-B2 and MBP-B2 C213A-A216V
View article: Supplementary Movie S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Movie S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Supplementary movie 2 shows Incomplete PML NBs fusion upon ATO treatment (1µM, 1h) in MEFs
View article: Supplementary Table S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying all the reagents used in this study with information regarding the supplier, catalog number and RRID (antibodies).
View article: Supplementary Figure S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S4 illustrates how trivalent arsenic binding to C213 in the B2 trimer leads to PML NB aggregation, and defective sumoylation and degradation of the trimer mutants, as well as the role of C213 mutants on PML partner localization and …
View article: Supplementary Movie S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Movie S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Supplementary movie 1 shows PML NBs fusion in MEFs, where two PML NBs undergo complete fusion and relaxation into one body
View article: Supplementary Table S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying the cell lines used in this study with their origin/RRID
View article: Supplementary Figure S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S4 illustrates how trivalent arsenic binding to C213 in the B2 trimer leads to PML NB aggregation, and defective sumoylation and degradation of the trimer mutants, as well as the role of C213 mutants on PML partner localization and …
View article: Supplementary Figure S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S2 shows Crystal structure of MBP-B2 fusion protein, and the similarity between the 3D structure of PML B2 and other TRIM proteins, yet its formation relies on specific amino acids
View article: Supplementary Figure S5 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S5 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S5 displays how B2 trimer is essential for PML-RARA microspeckle formation in progenitors and PML NB disruption as well as PML/RARA degradation ex vivo, as well as for PML NB formation and sumoylation in vivo
View article: Data from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Data from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
PML nuclear bodies (NB) are disrupted in PML-RARA–driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation. In non-APL cells, arsenic binding onto PML…
View article: Supplementary Table S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying the cell lines used in this study with their origin/RRID
View article: Supplementary Table S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S4 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying the information regarding the data collection and refinement statistics for the crystal structures of MBP-B2 and MBP-B2 C213A-A216V
View article: Supplementary Movie S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Movie S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Supplementary movie 2 shows Incomplete PML NBs fusion upon ATO treatment (1µM, 1h) in MEFs
View article: Supplementary Figure S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S1 illustrates LLPS hallmarks of PML nuclear bodies and highlights that their assembly does not rely on intermolecular disulfide bonds
View article: Supplementary Table S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying the primers used for site-directed mutagenesis.
View article: Supplementary Movie S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Movie S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Supplementary movie 1 shows PML NBs fusion in MEFs, where two PML NBs undergo complete fusion and relaxation into one body
View article: Supplementary Figure S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S3 shows that PML B2 trimer controls NB distribution and dynamics ranging from a liquid-like bodies to filaments
View article: Supplementary Figure S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S1 illustrates LLPS hallmarks of PML nuclear bodies and highlights that their assembly does not rely on intermolecular disulfide bonds
View article: Supplementary Figure S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S2 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S2 shows Crystal structure of MBP-B2 fusion protein, and the similarity between the 3D structure of PML B2 and other TRIM proteins, yet its formation relies on specific amino acids
View article: Supplementary Figure S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Figure S3 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Figure S3 shows that PML B2 trimer controls NB distribution and dynamics ranging from a liquid-like bodies to filaments
View article: Supplementary Table S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Supplementary Table S1 from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
Table displaying the primers used for site-directed mutagenesis.
View article: Data from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function
Data from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function Open
PML nuclear bodies (NB) are disrupted in PML-RARA–driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation. In non-APL cells, arsenic binding onto PML…